David J. Pinato, MD, PhD | Authors


Optimizing Treatment Approaches for Hepatocellular Carcinoma

March 10, 2020

David J. Pinato, MD, PhD, discusses the importance of utilizing a multidisciplinary approach when treating patients with hepatocellular carcinoma and how this approach helps optimize patient outcomes now as well as how it will help in the near future as more therapies emerge.

Adverse Events Inform Treatment Decisions in HCC for Frontline Lenvatinib Versus Sorafenib

September 25, 2019

David J. Pinato, MD, PhD, discusses the approach to selecting the appropriate frontline agent for patients with hepatocellular carcinoma. Sorafenib has been around for many years, but now that lenvatinib is FDA approved as well, physicians can now choose between the 2 agents.

Intra-Tumor Heterogeneity in Primary and Metastatic HCC

July 11, 2017

David J. Pinato, MD, PhD, NIHR Academic Clinical Lecturer in Medical Oncology, resident, Royal Brompton Hospital and Imperial College London, discusses an analysis of intra-tumor heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma (HCC).